BeStock  
Stocks › ABUS

Arbutus Biopharma ABUS

US equityMarket cap rank #3392
$4.08 −$0.21 (-4.96%)
Market open · Oct 8, 11:40 am ET · After hours $4.30 +0.23%
Open$4.22
Prev close$4.29
Day range$4.05 – $4.30
Volume1.62M
Market cap$807.76M
P/E (TTM)5.2
Dividend yield–

Fundamentals

Latest reported quarter: Q2, ended Jun 2026

Revenue$1.01M-90.6% YoY
Operating profit-$5.75M-400.6% YoY
Net profit-$5.14M-303.8% YoY
Diluted EPS-$0.03-400.0% YoY
Free cash flow-$6.02M+61.8% YoY
Operating cash flow-$6.02M

Revenue, last 8 quarters

$1.3MSep '24$1.6MDec '24$1.8MMar '25$10.7MJun '25$529.0KSep '25$1.1MDec '25$179.1MMar '26$1.0MJun '26

Net profit, last 8 quarters

$-19.7MSep '24$-12.5MDec '24$-24.5MMar '25$2.5MJun '25$-7.7MSep '25$-3.8MDec '25$169.7MMar '26$-5.1MJun '26

Diluted EPS by quarter

-0.10Sep '24-0.07Dec '24-0.13Mar '250.01Jun '25-0.04Sep '25-0.01Dec '250.87Mar '26-0.03Jun '26

Free cash flow by quarter

$-20.7MSep '24$-10.4MDec '24$-13.4MMar '25$-15.7MJun '25$-5.8MSep '25$-4.7MDec '25$-8.1MMar '26$-6.0MJun '26

Annual revenue

$6.9MFY20$11.0MFY21$39.0MFY22$18.1MFY23$6.2MFY24$14.1MFY25

Profitability & balance sheet

Operating margin81.1%
Net margin84.2%
Return on equity89.6%
Return on assets81.1%
Return on invested capital88.0%
Current ratio81.42
Liabilities / assets5.6%
Cash & investments$92.63M
Total debt$0.00
Net cash (debt)$92.63M

Income statement

Line item 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4 2025 Q3
Total Revenue as Reported $1.01M $179.13M $14.08M $1.05M $529,000.00
Total Operating Revenue $1.01M $179.13M $14.08M $1.05M $529,000.00
Operating Expense $6.77M $10.01M $41.13M $8.70M $8.82M
Selling and Admin Expenses $3.87M $5.89M $15.89M $3.69M $3.04M
-General & Admin Expense $3.87M $5.89M $15.89M $3.69M $3.04M
Research & Development $2.90M $4.12M $25.24M $5.01M $5.78M
Operating Profit -$5.75M $169.12M -$27.05M -$7.64M -$8.29M
Net Non-Operating Interest Income (Expense) $824,000.00 $798,000.00 $3.97M $859,000.00 $929,000.00
Non-Operating Interest Income $842,000.00 $815,000.00 $4.07M $877,000.00 $952,000.00
Non-Operating Interest Expense $18,000.00 $17,000.00 $97,000.00 $18,000.00 $23,000.00
Other Income (Expense) -$216,000.00 -$220,000.00 -$10.42M $3.03M -$378,000.00
Gain on Sale of Security -$3,000.00 -$11,000.00 $14,000.00 $1,000.00 -$12,000.00
Special Income (Charges) -$213,000.00 -$209,000.00 -$10.44M $3.03M -$366,000.00
-Less:Restructuring and Mergern & Acquisition $213,000.00 $209,000.00 $11.11M -$2.35M $366,000.00
Pretax Profit -$5.14M $169.70M -$33.50M -$3.76M -$7.74M
Net Profit -$5.14M $169.70M -$33.50M -$3.76M -$7.74M
Profit from Continuing Operations -$5.14M $169.70M -$33.50M -$3.76M -$7.74M
Net Income to Parent Company -$5.14M $169.70M -$33.50M -$3.76M -$7.74M
Net Income to Common Stockholders -$5.14M $169.70M -$33.50M -$3.76M -$7.74M
Basic EPS -$0.03 $0.88 -$0.17 -$0.01 -$0.04
Diluted EPS -$0.03 $0.87 -$0.17 -$0.01 -$0.04
-Gain on Sale of Property/Plant/Equipment – – $674,000.00 – –

Balance sheet

Line item 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4 2025 Q3
Total Assets $274.03M $277.16M $94.62M $94.62M $97.71M
Total Current Assets $273.88M $277.01M $94.46M $94.46M $97.44M
Cash and Cash Equivalents & Short-Term Investments $92.63M $95.23M $91.47M $91.47M $93.70M
-Cash and Cash Equivalents $19.17M $23.71M $18.01M $18.01M $22.41M
-Short Term Investments $73.45M $71.52M $73.46M $73.46M $71.29M
Receivables $179.74M $180.05M $1.45M $1.45M $905,000.00
-Accounts Receivable $369,000.00 $1.31M $1.45M $1.45M $905,000.00
-Other Receivables $179.37M $178.74M – – –
Other Current Assets $1.52M $1.73M $1.54M $1.54M $2.84M
Total Non-Current Assets $142,000.00 $153,000.00 $162,000.00 $162,000.00 $268,000.00
Net PPE $10,000.00 $22,000.00 $32,000.00 $32,000.00 $137,000.00
-Gross PPE $245,000.00 $246,000.00 $245,000.00 $245,000.00 $13.48M
-Accumulated Depreciation -$235,000.00 -$224,000.00 -$213,000.00 -$213,000.00 -$13.35M
Other Non-Current Assets $132,000.00 $131,000.00 $130,000.00 $130,000.00 $131,000.00
Total Liabilities $15.29M $16.99M $18.04M $18.04M $20.31M
Total Current Liabilities $3.36M $5.11M $6.01M $6.01M $5.18M
Payables $373,000.00 $1.46M $1.17M $1.17M $1.01M
-Accounts Payable $373,000.00 $1.46M $1.17M $1.17M $1.01M
Current Accrued Expenses $2.32M $2.77M $3.65M $3.65M $2.88M
Short-Term Debt and Capital Lease Obligation $514,000.00 $631,000.00 $547,000.00 $547,000.00 $531,000.00
-Current Capital Lease Obligation $514,000.00 $631,000.00 $547,000.00 $547,000.00 $531,000.00
Other Current Liabilities $160,000.00 $245,000.00 $640,000.00 $640,000.00 $763,000.00
Total Non-Current Liabilities $11.93M $11.88M $12.04M $12.04M $15.13M
Long Term Debt and Capital Lease Obligation $0.00 $0.00 $199,000.00 $199,000.00 $391,000.00
-Long Term Capital Lease Obligation $0.00 $0.00 $199,000.00 $199,000.00 $391,000.00
Other Non-Current Liabilities $11.93M $11.88M $11.84M $11.84M $14.74M
Total Equity $258.73M $260.18M $76.58M $76.58M $77.40M
Stockholders' Equity $258.73M $260.18M $76.58M $76.58M $77.40M
Capital Stock $1.45B $1.44B $1.42B $1.42B $1.42B
-Common Stock $1.45B $1.44B $1.42B $1.42B $1.42B
Additional Paid-In Capital $74.32M $74.26M $83.32M $83.32M $83.29M
Retained Earnings -$1.22B -$1.21B -$1.38B -$1.38B -$1.38B
Gains/Losses Not Affecting Retained Earnings -$48.24M -$48.20M -$48.10M -$48.10M -$48.13M
Current Deferred Liabilities – – $0.00 $0.00 $0.00
Non-Current Deferred Liabilities – – $0.00 $0.00 $0.00

Cash flow

Line item 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4 2025 Q3
Operating Cash Flow -$6.02M -$8.11M -$39.64M -$4.68M -$5.82M
Net cash flow from continuing operations -$6.02M -$8.11M -$39.64M -$4.68M -$5.82M
Net Income from Continuing Operations -$5.14M $169.70M -$33.50M -$3.76M -$7.74M
Depreciation & Depletion & Amortization $11,000.00 $11,000.00 $363,000.00 $11,000.00 $11,000.00
Other Non-Cash Items $46,000.00 $45,000.00 -$3.22M -$2.90M $42,000.00
Change in Working Capital -$2.24M -$178.87M -$10.02M $1.80M $1.15M
-Change in Receivables -$179.46M $1.16M $1.38M -$129,000.00 $120,000.00
-Change in Prepaid Assets $215,000.00 -$195,000.00 $1.70M $1.30M $1.04M
-Change in Payables and Accrued Expense -$1.62M -$985,000.00 -$2.11M $806,000.00 $145,000.00
-Change in Other Current Liabilities -$113,000.00 -$105,000.00 -$557,000.00 -$177,000.00 -$155,000.00
Net cash flow from investing -$1.66M $2.20M $15.58M -$1.36M -$10.02M
Net Cash Flow from Continuing Investing Activities -$1.66M $2.20M $15.58M -$1.36M -$10.02M
Net Investment Purchase and Sale -$1.66M $2.20M $15.22M -$1.72M -$10.02M
Financing Cash Flow $3.15M $11.62M $5.72M $1.64M $844,000.00
Net Cash Flow from Continuing Financing Activities $3.15M $11.62M $5.72M $1.64M $844,000.00
Proceeds from Stock Option Exercised $3.15M $11.62M $5.72M $1.64M $844,000.00
Ending Cash Balance $19.17M $23.71M $18.01M $18.01M $22.41M
Net Change in Cash -$4.53M $5.71M -$18.34M -$4.40M -$14.99M
Beginning Cash Balance $23.71M $18.01M $36.33M $22.41M $37.41M
Effect of Exchange Rate Changes -$4,000.00 -$10,000.00 $14,000.00 $1,000.00 -$12,000.00
Free Cash Flow -$6.02M -$8.11M -$39.64M -$4.68M -$5.82M
-Change In Other Working Capital – -$178.74M -$10.43M $0.00 $0.00
Net Other Investing Changes – -$1,000.00 – – –
Gain/Loss from Continuing Operations – – -$674,000.00 – –
Net PPE Purchase and Sale – – $364,000.00 $355,000.00 $0.00
Net Common Stock Issuance – – $0.00 $0.00 –

Discussion

No comments yet — be the first to weigh in on ABUS.

Leave a comment

Scroll to Top